GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (NAS:SNDX) » Definitions » E10

Syndax Pharmaceuticals (Syndax Pharmaceuticals) E10 : $-4.79 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Syndax Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Syndax Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.850. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-4.79 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-25), Syndax Pharmaceuticals's current stock price is $20.28. Syndax Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-4.79. Syndax Pharmaceuticals's Shiller PE Ratio of today is .


Syndax Pharmaceuticals E10 Historical Data

The historical data trend for Syndax Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals E10 Chart

Syndax Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -5.39 -4.63

Syndax Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.54 -5.62 -4.74 -4.63 -4.79

Competitive Comparison of Syndax Pharmaceuticals's E10

For the Biotechnology subindustry, Syndax Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Shiller PE Ratio falls into.



Syndax Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Syndax Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.85/131.7762*131.7762
=-0.850

Current CPI (Mar. 2024) = 131.7762.

Syndax Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.952 100.560 -1.248
201409 -1.635 100.428 -2.145
201412 -0.782 99.070 -1.040
201503 -1.817 99.621 -2.403
201506 -3.965 100.684 -5.189
201509 -8.529 100.392 -11.195
201512 -0.505 99.792 -0.667
201603 -2.850 100.470 -3.738
201606 -0.470 101.688 -0.609
201609 -0.840 101.861 -1.087
201612 -0.590 101.863 -0.763
201703 -0.710 102.862 -0.910
201706 -0.700 103.349 -0.893
201709 -0.680 104.136 -0.860
201712 -0.800 104.011 -1.014
201803 -0.790 105.290 -0.989
201806 -0.740 106.317 -0.917
201809 -0.680 106.507 -0.841
201812 -0.700 105.998 -0.870
201903 -0.530 107.251 -0.651
201906 -0.470 108.070 -0.573
201909 -0.410 108.329 -0.499
201912 -0.440 108.420 -0.535
202003 -0.560 108.902 -0.678
202006 -0.420 108.767 -0.509
202009 -0.460 109.815 -0.552
202012 -0.440 109.897 -0.528
202103 -0.540 111.754 -0.637
202106 -0.440 114.631 -0.506
202109 -0.400 115.734 -0.455
202112 1.810 117.630 2.028
202203 -0.630 121.301 -0.684
202206 -0.620 125.017 -0.654
202209 -0.580 125.227 -0.610
202212 -0.620 125.222 -0.652
202303 -0.590 127.348 -0.611
202306 -0.640 128.729 -0.655
202309 -0.730 129.860 -0.741
202312 -1.000 129.419 -1.018
202403 -0.850 131.776 -0.850

Add all the adjusted EPS together and divide 10 will get our e10.


Syndax Pharmaceuticals  (NAS:SNDX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Syndax Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Syndax Pharmaceuticals (Syndax Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, Building D, Floor 3, Waltham, MA, USA, 02451
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Executives
Briggs Morrison director, officer: Chief Executive Officer C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
William Meury director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Neil Gallagher officer: President, Head of R&D 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Peter Ordentlich officer: Chief Technology Officer C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Michael A Metzger officer: President and COO C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Steve M Sabus officer: Chief Commercial Officer 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Catherine Madigan officer: Chief Medical Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Alexander Nolte officer: Chief Accounting Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Fabrice Egros director C/O SYNDAX PHARMACEUTICALS, INC., TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Huber Martin H. Jr. director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Daphne Karydas officer: Chief Financial Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451

Syndax Pharmaceuticals (Syndax Pharmaceuticals) Headlines

From GuruFocus